ArticleClinical and translational radiation oncology2022
Online adaptive radiotherapy for head and neck cancers on the MR linear Accelerator: Introducing a novel modified Adapt-to-Shape approach.
Article in Clinical and translational radiation oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Dosimetric impact of baseline shift plan in a magnetic resonance linear accelerator according to target motion and plan characteristics.Journal of applied clinical medical physics · 2026Article
- Deep learning-enhanced image registration for accelerating daily adaptive magnetic resonance imaging-guided prostate radiotherapy.Physics and imaging in radiation oncology · 2026Article
- Optimal timing of the cumulative dose and factors related to acute urinary toxicity in prostate cancer treated using magnetic resonance linear accelerator.Radiological physics and technology · 2026Article
- Adapting to the Future: Introducing the Radiation Oncology Alliance Adaptive Radiotherapy Working Group.Journal of medical imaging and radiation oncology · 2025Article
- Patient experience of head and neck treatment on a 1.5 T MR-Linac: is the ATS-lite adaptive solution tolerable?Technical innovations & patient support in radiation oncology · 2025Article
- Development of in-house software to process real-time cine magnetic resonance images acquired during 1.5 T MR-guided radiation therapy.Scientific reports · 2025Article
- Adaptive radiotherapy for oropharyngeal cancer with daily adapt-to-shape workflow on 1.5 T MRI-linac: Preliminary outcomes and comparison with helical tomotherapy.Clinical and translational radiation oncology · 2025Article
- Effect of respiration-induced motion on a three-dimensional magnetic resonance imaging-based adaptive radiotherapy workflow in a 1.5T magnetic resonance linear accelerator.Quantitative imaging in medicine and surgery · 2025Article
- Risk analysis of the Unity 1.5T MR-Linac adapt-to-shape workflow.Journal of applied clinical medical physics · 2025Article
- Treatment of Non-Hodgkin Lymphoma Involving Head and Neck Sites with a 1.5 T MR-Linac: Preliminary Results from a Prospective Observational Study.Hematology reports · 2025Article
- Treatment time and learning curve analysis of 1.5 T MR-Linac workflows led by radiation oncologists or therapists.Clinical and translational radiation oncology · 2025Article
- Dosimetric effects of bladder volume changes in MR-guided radiotherapy for cervical cancer.BMC cancer · 2025Article
- A simplified online adaptive workflow for long-course magnetic resonance-guided radiotherapy in esophageal cancer.Physics and imaging in radiation oncology · 2025Article
- Feasibility of creating a daily adaptive plan using automatic DIR-created target and OARs contours in patients with prostate cancer magnetic-resonance-guided adaptive radiotherapy.Journal of radiation research · 2024Article
- Article
- Adaptive assessment based on fractional CBCT images for cervical cancer.Journal of applied clinical medical physics · 2024Article
- Clinical Experience With an Offline Adaptive Radiation Therapy Head and Neck Program: Dosimetric Benefits and Opportunities for Patient Selection.International journal of radiation oncology, biology, physics · 2024Article
- Measurement and Incorporation of Laryngeal Motion Using cine-MRI on an MR-Linear Accelerator to Generate Radiation Therapy Plans for Early-stage Squamous Cell Cancers of the Glottis.Advances in radiation oncology · 2024Article
- The Use of MR-Guided Radiation Therapy for Head and Neck Cancer and Recommended Reporting Guidance.Seminars in radiation oncology · 2024Review
- In Silico Analysis of Adjuvant Head and Neck Online Adaptive Radiation Therapy.Advances in radiation oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
introductionThe Elekta Unity MR-Linac (MRL) has enabled adaptive radiotherapy (ART) for patients with head and neck cancers (HNC). Adapt-To-Shape-Lite (ATS-Lite) is a novel Adapt-to-Shape strategy that provides ART without requiring daily clinician presence to perform online target and organ at risk (OAR) delineation. In this study we compared the performance of our clinically-delivered ATS-Lite strategy against three Adapt-To-Position (ATP) variants: Adapt Segments (ATP-AS), Optimise Weights (ATP-OW), and Optimise Shapes (ATP-OS).
methodsTwo patients with HNC received radical-dose radiotherapy on the MRL. For each fraction, an ATS-Lite plan was generated online and delivered and additional plans were generated offline for each ATP variant. To assess the clinical acceptability of a plan for every fraction, twenty clinical goals for targets and OARs were assessed for all four plans.
results53 fractions were analysed. ATS-Lite passed 99.9% of mandatory dose constraints. ATP-AS and ATP-OW each failed 7.6% of mandatory dose constraints. The Planning Target Volumes for 54 Gy (D95% and D98%) were the most frequently failing dose constraint targets for ATP. ATS-Lite median fraction times for Patient 1 and 2 were 40 mins 9 s (range 28 mins 16 s - 47 mins 20 s) and 32 mins 14 s (range 25 mins 33 s - 44 mins 27 s), respectively.
conclusionsOur early data show that the novel ATS-Lite strategy produced plans that fulfilled 99.9% of clinical dose constraints in a time frame that is tolerable for patients and comparable to ATP workflows. Therefore, ATS-Lite, which bridges the gap between ATP and full ATS, will be further utilised and developed within our institute and it is a workflow that should be considered for treating patients with HNC on the MRL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.